BBOT Stock Analysis: Buy, Sell, or Hold?
BBOT - BridgeBio Oncology Therapeutics, Inc. Common Stock
$2.85
0.17 (6.34%)
▲
5d:
-3.39%
30d:
-31.49%
90d:
-67.69%
WAIT
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 11, 2026
18d
Get Alerted When BBOT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: BBOT shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: BBOT shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: BBOT is currently trading at $2.85, which is considered oversold relative to its 30-day fair value range of $3.01 to $4.49.
Technical Outlook: Technically, BBOT is in a strong downtrend. Immediate support is located at $2.66, while resistance sits at $3.50. The stock is showing strong short-term momentum, up 6.3% recently.
Market Sentiment: BBOT scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $23.55 (+726.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BBOT is in a strong downtrend. Immediate support is located at $2.66, while resistance sits at $3.50. The stock is showing strong short-term momentum, up 6.3% recently.
Market Sentiment: BBOT scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $23.55 (+726.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.01 -
$4.49
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
100.0%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+6.3%)
- BULLISH: Trading 726.2% below Wall St target ($23.55)
- WARNING: Composite score 53/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.01 -
$4.49
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.66
Resistance Level
$3.50
Current Trend
Strong Downtrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.03
Wall Street Target
$23.55
(+726.2%)
Share & Embed Analysis
Last updated: October 23, 2026 8:40 AM ET
Data refreshes hourly during market hours. Next update: 9:40 AM
Data refreshes hourly during market hours. Next update: 9:40 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BBOT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
20 analysts |
$36 | 68 BUY |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
18 analysts |
$70 | 71 BUY |
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
20 analysts |
$17 | 60 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
14 analysts |
$153 | 68 BUY |
|
ARWR
Arrowhead Pharmaceutical… |
STRONG BUY
15 analysts |
$108 | 60 BUY |
